Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s002800050425PMID 8612306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations

  2004cited by this paper
• Lipid bilayer partitioning and stability of camptothecin drugs.

  1993cited by this paper
• Biodistribution of Micelle-Forming Polymer–Drug Conjugates

  1993cited by this paper
• The current status of camptothecin analogues as antitumor agents.

  1993cited by this paper
• Preferential binding of the carboxylate form of camptothecin by human serum albumin.

  1993cited by this paper
• The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B.

  1992cited by this paper
• Liposomal stabilization of camptothecin's lactone ring

  1992cited by this paper
• Structural modifications of camptothecin and effects on topoisomerase I inhibition.

  1992cited by this paper
• Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.

  1991cited by this paper
• Determination of camptothecin in biological fluids using reversed-phase high-performance liquid chromatography with fluorescence detection.

  1990cited by this paper
• Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells.

  1990cited by this paper
• Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.

  1989cited by this paper
• Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

  1989cited by this paper
• Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

  1989cited by this paper
• Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

  1988cited by this paper
• Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.

  1987cited by this paper
• Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

  1985cited by this paper
• Introduction of liposome-encapsulated SV40 DNA into cells.

  1980cited by this paper
• Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

  1972cited by this paper
• Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

  1972cited by this paper
• Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

  1970cited by this paper
• A fluorometric method for determination of camptothecin in plasma and urine.

  1969cited by this paper
• Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

  1966cited by this paper

• Arjunolic acid from Rhodomyrtus tomentosa Suppresses Growth of Non-Small Cell Lung Cancer via Inducing Autophagy and Apoptosis

  2025cites this paper
• Development and statistical optimization of camptothecin loaded hyaluronic acid and zein polymeric nanoparticles towards the treatment of melanoma.

  2025cites this paper
• Ultrasound-triggered drug release and cytotoxicity of microbubbles with diverse drug attributes

  2024cites this paper
• Polymeric Micelles Coated with Hybrid Nanovesicles Enhance the Therapeutic Potential of the Reversible Topoisomerase Inhibitor Camptothecin in a Mouse Model.

  2020cites this paper
• Anticancer Activity of the Host-Guest Complex of Camptothecin with β-Cyclodextrin-Folate Conjugate. Encapsulation and Efficacy

  2020cites this paper
• Topoisomerase inhibitors: pharmacology and emerging nanoscale delivery systems.

  2019cites this paper
• Lipid-drug conjugates: a potential nanocarrier system for oral drug delivery applications

  2018cites this paper
• Preparation, characterization and in vitro evaluation of calothrixin B liposomes

  2018cites this paper
• Safe approaches for camptothecin delivery: Structural analogues and nanomedicines

  2017cites this paper
• Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease.

  2017cites this paper
• Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform.

  2016cites this paper
• Preparation and evaluation of lipid vesicles of camptothecin as targeted drug delivery system.

  2013cites this paper
• Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution

  2013influential citation
• Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin.

  2013cites this paper
• Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin

  2013influential citation
• EMULSOMES: AN EMERGING VESICULAR DRUG DELIVERY SYSTEM

  2013cites this paper
• Nano-particulate Drug Delivery Systems for CamptothecinsArticle

  2012cites this paper
• Investigation and optimization of liposome formulation for use as drug carrier for the anticancer agent Camptothecin

  2011cites this paper
• Caleosin-assembled oil bodies as a potential delivery nanocarrier

  2011cites this paper
• Functionalized nanoscale oil bodies for targeted delivery of a hydrophobic drug

  2011cites this paper
• Caleosin-based nanoscale oil bodies for targeted delivery of hydrophobic anticancer drugs

  2011cites this paper
• THESIS FOR THE DEGREE MASTER OF PHARMACY INVESTIGATION AND OPTIMIZATION OF LIPOSOME FORMULATION FOR USE AS DRUG CARRIER FOR THE ANTICANCER AGENT CAMPTOTHECIN BY ELENAZ NADERKHANI

  2011cites this paper
• Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

  2010cites this paper
• Kilogram Scale Synthesis of a Triazine-based Dendrimer and the Development of a General Strategy for the Installation of Pharmacophores to Yield Potential Drug Delivery Agents

  2009cites this paper
• Preparations and properties of hydroxycamptothecin emulsion and its tissue distribution in mice

  2009cites this paper
• Improved cyclodextrin-based receptors for camptothecin by inverse virtual screening.

  2007cites this paper
• In Vitro andIn Vivo Studies of Different Liposomes Containing Topotecan

  2005cites this paper
• In‐vitro cytotoxicity, in‐vivo biodistribution and anti‐tumour effect of PEGylated liposomal topotecan

  2005cites this paper
• A method to determine the incorporation capacity of camptothecin in liposomes

  2004cites this paper
• Novel Camptothecin Analogue (Gimatecan)‐Containing Liposomes Prepared by the Ethanol Injection Method

  2004cites this paper
• Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro

  2004cites this paper
• Camptothecins and lung cancer: improved delivery systems by aerosol.

  2003cites this paper
• Targeted Delivery of Doxorubicin by HPMA Copolymer-Hyaluronan Bioconjugates

  2002cites this paper
• Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.

  2002cites this paper
• Camptothecin Delivery Methods

  2002cites this paper
• Improved Dissolution and Cytotoxicity of Camptothecin Incorporated into Oxidized-Cellulose Microspheres Prepared by Spray Drying

  2001cites this paper
• Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies

  2001cites this paper
• Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice

  2001cites this paper
• Alternative Administration of Camptothecin Analogues

  2000cites this paper
• Liposomal delivery of camptothecins.

  2000cites this paper
• Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice

  1999cites this paper
• CHAPTER 4.5 – Liposomes as carriers of lipophilic antitumor agents

  1998cites this paper
• Topoisomerase I inhibitors and drug resistance

  1998cites this paper
• Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.

  1998cites this paper
• Multiple Drug Resistance in Cancer 2

  1998cites this paper
• Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity.

  1996cites this paper